Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Shiryaev N, Pikman R, Giladi E, Gozes I.

Curr Pharm Des. 2011;17(25):2603-12. Review.

PMID:
21728979
2.

NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Gozes I, Divinski I, Piltzer I.

BMC Neurosci. 2008 Dec 10;9 Suppl 3:S3. doi: 10.1186/1471-2202-9-S3-S3.

3.

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

Gozes I.

Curr Pharm Des. 2011;17(31):3413-7. Review.

PMID:
21902667
4.

NAP alpha-aminoisobutyric acid (IsoNAP).

Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.

J Mol Neurosci. 2014 Jan;52(1):1-9. doi: 10.1007/s12031-013-0103-8.

PMID:
24458740
5.
6.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.

J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.

7.

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Oz S, Ivashko-Pachima Y, Gozes I.

PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.

8.

Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.

J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.

PMID:
24503616
10.

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.

PMID:
15665412
11.

A novel peptide prevents death in enriched neuronal cultures.

Zemlyak I, Furman S, Brenneman DE, Gozes I.

Regul Pept. 2000 Dec 22;96(1-2):39-43.

PMID:
11102650
12.

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I.

Neurobiol Dis. 2009 May;34(2):381-8. doi: 10.1016/j.nbd.2009.02.011. Epub 2009 Mar 2.

PMID:
19264130
13.

NAP (davunetide) provides functional and structural neuroprotection.

Gozes I.

Curr Pharm Des. 2011;17(10):1040-4. Review.

PMID:
21524250
15.

Activity-dependent neuroprotective protein: from gene to drug candidate.

Gozes I.

Pharmacol Ther. 2007 May;114(2):146-54. Epub 2007 Feb 1. Review.

PMID:
17363064
16.

From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.

Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD.

J Mol Neurosci. 2003;20(3):315-22. Review.

PMID:
14501014
17.

The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.

Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I.

Peptides. 2005 Aug;26(8):1520-7. Epub 2005 Apr 15.

PMID:
16042992
18.

Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.

Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P.

Neuroscience. 2011 Jan 26;173:156-68. doi: 10.1016/j.neuroscience.2010.10.074. Epub 2010 Nov 10.

PMID:
21073926
19.

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

Magen I, Gozes I.

Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.

PMID:
24210139
20.

Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.

Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, Pozo D.

J Mol Neurosci. 2010 May;41(1):114-20. doi: 10.1007/s12031-009-9300-x. Epub 2009 Oct 21.

PMID:
19844808
Items per page

Supplemental Content

Write to the Help Desk